OGDHL is a modifier of AKT-dependent signaling and NF-κB function.

PubWeight™: 0.87‹?›

🔗 View Article (PMC 3495966)

Published in PLoS One on November 12, 2012

Authors

Tanusree Sen1, Nilkantha Sen, Maartje G Noordhuis, Rajani Ravi, T-C Wu, Patrick K Ha, David Sidransky, Mohammad Obaidul Hoque

Author Affiliations

1: Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.

Articles cited by this

Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28

Predicting subcellular localization of proteins based on their N-terminal amino acid sequence. J Mol Biol (2000) 22.77

Nuclear factor-kappaB in cancer development and progression. Nature (2006) 18.31

PSORT: a program for detecting sorting signals in proteins and predicting their subcellular localization. Trends Biochem Sci (1999) 14.36

CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet (2006) 13.63

NF-kappaB at the crossroads of life and death. Nat Immunol (2002) 12.98

NF-kappa B: ten years after. Cell (1996) 12.80

Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science (1996) 12.23

Computational method to predict mitochondrially imported proteins and their targeting sequences. Eur J Biochem (1996) 10.23

Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci (2001) 6.66

The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal (2002) 6.35

Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest (2001) 5.87

Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer (2006) 5.87

Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet (2007) 5.81

Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science (1988) 4.93

Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res (2005) 4.74

The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene (2005) 3.42

Mitochondrial alpha-ketoglutarate dehydrogenase complex generates reactive oxygen species. J Neurosci (2004) 2.57

Role of redox potential and reactive oxygen species in stress signaling. Oncogene (1999) 2.37

Mutagenicity of arsenic in mammalian cells: role of reactive oxygen species. Proc Natl Acad Sci U S A (1998) 2.12

Generation of reactive oxygen species in the reaction catalyzed by alpha-ketoglutarate dehydrogenase. J Neurosci (2004) 1.97

Rel/NF-kappa B/I kappa B story. Adv Cancer Res (1995) 1.83

Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer (2009) 1.80

Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer. Cancer Res (2003) 1.77

Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res (2008) 1.70

p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res (2003) 1.62

Mitochondrial dysfunction in neurodegenerative diseases and cancer. Environ Mol Mutagen (2010) 1.60

Carbon monoxide differentially modulates STAT1 and STAT3 and inhibits apoptosis via a phosphatidylinositol 3-kinase/Akt and p38 kinase-dependent STAT3 pathway during anoxia-reoxygenation injury. J Biol Chem (2004) 1.54

Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer's disease. Arch Neurol (1988) 1.48

Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res (2000) 1.46

Vanadate-induced expression of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor through phosphatidylinositol 3-kinase/Akt pathway and reactive oxygen species. J Biol Chem (2002) 1.41

NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma. Mol Cancer (2010) 1.33

Transforming growth factor-β1 induces matrix metalloproteinase-9 and cell migration in astrocytes: roles of ROS-dependent ERK- and JNK-NF-κB pathways. J Neuroinflammation (2010) 1.24

Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer. Cancer Treat Rev (2003) 1.19

Coexpression of Notch1 and NF-kappaB signaling pathway components in human cervical cancer progression. Gynecol Oncol (2006) 1.18

Ras-mediated loss of the pro-apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells. J Biol Chem (2005) 1.18

betaA3/A1-crystallin in astroglial cells regulates retinal vascular remodeling during development. Mol Cell Neurosci (2007) 1.18

Redox homeostasis and cellular stress response in aging and neurodegeneration. Methods Mol Biol (2010) 1.18

Regulation of p53 family member isoform DeltaNp63alpha by the nuclear factor-kappaB targeting kinase IkappaB kinase beta. Cancer Res (2010) 1.11

Structure-function relationships in the 2-oxo acid dehydrogenase family: substrate-specific signatures and functional predictions for the 2-oxoglutarate dehydrogenase-like proteins. Proteins (2008) 1.09

Localization of the site of oxygen radical generation inside the complex I of heart and nonsynaptic brain mammalian mitochondria. J Bioenerg Biomembr (2000) 1.07

ROS-driven Akt dephosphorylation at Ser-473 is involved in 4-HPR-mediated apoptosis in NB4 cells. Free Radic Biol Med (2009) 1.06

Critical upstream signals of cytochrome C release induced by a novel Bcl-2 inhibitor. J Biol Chem (2004) 1.06

15d-PGJ2 induces apoptosis by reactive oxygen species-mediated inactivation of Akt in leukemia and colorectal cancer cells and shows in vivo antitumor activity. Clin Cancer Res (2009) 1.06

Pharmacologic unmasking of epigenetically silenced genes in breast cancer. Clin Cancer Res (2009) 1.06

Decreased T cell ERK pathway signaling may contribute to the development of lupus through effects on DNA methylation and gene expression. Int Rev Immunol (2004) 0.94

Selective loss of KGDHC-enriched neurons in Alzheimer temporal cortex: does mitochondrial variation contribute to selective vulnerability? J Mol Neurosci (2001) 0.86

Caspase-3-mediated cleavage of Akt: involvement of non-consensus sites and influence of phosphorylation. FEBS Lett (2007) 0.85

An analysis of expression patterns of genes encoding proteins with catalytic activities. BMC Genomics (2007) 0.85

Rel/Nuclear factor-kappa B apoptosis pathways in human cervical cancer cells. Cancer Cell Int (2005) 0.84

Cellular localization of alpha-ketoglutarate: glyoxylate carboligase in rat tissues. Biochim Biophys Acta (1977) 0.84

Tricetin, a dietary flavonoid, induces apoptosis through the reactive oxygen species/c-Jun NH2-terminal kinase pathway in human liver cancer cells. J Agric Food Chem (2010) 0.78

Articles by these authors

Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12

Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res (2002) 7.09

BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst (2003) 6.20

TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med (2007) 5.92

Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med (2006) 5.80

Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA (2013) 5.71

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst (2003) 5.64

H2S signals through protein S-sulfhydration. Sci Signal (2009) 4.54

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab (2005) 4.39

Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell (2002) 3.12

Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnology (2007) 2.93

A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther (2011) 2.74

Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res (2008) 2.66

MicroRNA alterations in head and neck squamous cell carcinoma. Int J Cancer (2008) 2.56

The Human MitoChip: a high-throughput sequencing microarray for mitochondrial mutation detection. Genome Res (2004) 2.54

p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. J Natl Cancer Inst (2003) 2.54

A high-fat diet and regulatory T cells influence susceptibility to endotoxin-induced liver injury. Hepatology (2007) 2.52

DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development. Cancer Res (2003) 2.46

DNA methylation markers in colorectal cancer. Cancer Metastasis Rev (2010) 2.40

Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res (2004) 2.34

Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res (2011) 2.31

How will HPV vaccines affect cervical cancer? Nat Rev Cancer (2006) 2.23

GAPDH mediates nitrosylation of nuclear proteins. Nat Cell Biol (2010) 2.22

Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res (2005) 2.20

Aquaporin 1 is overexpressed in lung cancer and stimulates NIH-3T3 cell proliferation and anchorage-independent growth. Am J Pathol (2006) 2.19

Objective assessment in residency-based training for transoral robotic surgery. Laryngoscope (2012) 2.06

A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res (2004) 2.06

Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res (2003) 2.05

Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst (2006) 2.05

Mitochondrial C-tract alteration in premalignant lesions of the head and neck: a marker for progression and clonal proliferation. Clin Cancer Res (2002) 1.97

Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res (2002) 1.88

Patient-derived xenografts for individualized care in advanced sarcoma. Cancer (2014) 1.82

Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol (2005) 1.80

Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker. Clin Cancer Res (2004) 1.76

Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res (2004) 1.74

Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther (2004) 1.72

Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J Mol Med (Berl) (2006) 1.72

Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest (2003) 1.71

Tumor-specific changes in mtDNA content in human cancer. Int J Cancer (2005) 1.70

Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res (2008) 1.70

Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol (2006) 1.69

Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck. Proc Natl Acad Sci U S A (2007) 1.68

Endothelin receptor type B gene promoter hypermethylation in salivary rinses is independently associated with risk of oral cavity cancer and premalignancy. Cancer Prev Res (Phila) (2010) 1.68

Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J Clin Endocrinol Metab (2007) 1.66

Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. J Virol (2004) 1.66

Electrophile and oxidant damage of mitochondrial DNA leading to rapid evolution of homoplasmic mutations. Proc Natl Acad Sci U S A (2003) 1.66

Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res (2003) 1.65

Differential recognition of response elements determines target gene specificity for p53 and p63. Mol Cell Biol (2005) 1.63

Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin Cancer Res (2008) 1.62

Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res (2006) 1.62

A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med (2005) 1.61

Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. Cancer Res (2003) 1.59

Fine mapping of chromosome 3 in uveal melanoma: identification of a minimal region of deletion on chromosomal arm 3p25.1-p25.2. Cancer Res (2003) 1.59

Global DNA hypomethylation is associated with in utero exposure to cotinine and perfluorinated alkyl compounds. Epigenetics (2010) 1.57

Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine (2003) 1.56

Mitochondrial subversion in cancer. Cancer Prev Res (Phila) (2011) 1.54

Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab (2004) 1.54

Quantitative detection of Merkel cell virus in human tissues and possible mode of transmission. Int J Cancer (2010) 1.53

Real-time quantitative PCR demonstrates low prevalence of human papillomavirus type 16 in premalignant and malignant lesions of the oral cavity. Clin Cancer Res (2002) 1.53

Prospects of RNA interference therapy for cancer. Gene Ther (2006) 1.52

Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab (2005) 1.51

Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma. PLoS One (2015) 1.51

DeltaNp63 induces beta-catenin nuclear accumulation and signaling. Cancer Cell (2002) 1.51

Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. Expert Rev Vaccines (2007) 1.50

Sulfhydration mediates neuroprotective actions of parkin. Nat Commun (2013) 1.49

Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res (2004) 1.47

OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation. PLoS One (2008) 1.47

Mouse mammary tumor-like env gene as a molecular marker for breast cancer? Int J Cancer (2002) 1.47

Mitochondrial D-loop mutations as clonal markers in multicentric hepatocellular carcinoma and plasma. Clin Cancer Res (2002) 1.46

Molecular assessment of lymph nodes in patients with resected stage I non-small cell lung cancer: preliminary results of a prospective study. J Thorac Cardiovasc Surg (2002) 1.46

Involvement of aquaporins in colorectal carcinogenesis. Oncogene (2003) 1.45

Feasibility of quantitative PCR-based saliva rinse screening of HPV for head and neck cancer. Int J Cancer (2005) 1.45

DeltaNp63alpha up-regulates the Hsp70 gene in human cancer. Cancer Res (2005) 1.44

Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Res (2007) 1.43

Changes in CpG islands promoter methylation patterns during ductal breast carcinoma progression. Cancer Epidemiol Biomarkers Prev (2009) 1.43

Mitochondrial cytochrome B gene mutation promotes tumor growth in bladder cancer. Cancer Res (2008) 1.41

Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells. Gene Ther (2007) 1.40

An oligonucleotide microarray for high-throughput sequencing of the mitochondrial genome. J Mol Diagn (2006) 1.40

Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. Cancer Res (2007) 1.39

Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine (2009) 1.38

DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency. Mol Ther (2007) 1.37

An EGFR-ERK-SOX9 signaling cascade links urothelial development and regeneration to cancer. Cancer Res (2011) 1.37

Mitochondrial DNA quantity increases with histopathologic grade in premalignant and malignant head and neck lesions. Clin Cancer Res (2004) 1.37

Nanog signaling in cancer promotes stem-like phenotype and immune evasion. J Clin Invest (2012) 1.37

N-methyl-D-aspartate receptor type 2B is epigenetically inactivated and exhibits tumor-suppressive activity in human esophageal cancer. Cancer Res (2006) 1.36

Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer Res (2004) 1.35

PGP9.5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma. Cancer Res (2005) 1.34

Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer Res (2004) 1.32

Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res (2005) 1.32

Focus on endometrial and cervical cancer. Cancer Cell (2004) 1.32

RACK1 and stratifin target DeltaNp63alpha for a proteasome degradation in head and neck squamous cell carcinoma cells upon DNA damage. Cell Cycle (2004) 1.31

Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res (2005) 1.30

Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J Virol (2004) 1.30